Navigation Links
Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
Date:8/11/2009

nd reducing pain in the early postoperative period," said Gregory A. Demopulos, M.D., Chairman and CEO of Omeros. "We are moving ahead with additional studies to determine optimal dosing of OMS302's mydriatic and anti-inflammatory agents."

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery((TM)) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery((TM)) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. For more information on Omeros, visit the Company's Web site at www.omeros.com.


'/>"/>
SOURCE Omeros Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
2. Omeros Appoints David A. Mann to its Board of Directors
3. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
4. Omeros and BlueCrest Announce $20 Million Debt Facility
5. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
6. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
7. Omeros Appoints New Vice President of Clinical Development
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... August 21, 2014 The College of ... private college in the Mid-Hudson Region to be designated ... begin accepting applications from qualified “high-technology” businesses that align ... very pleased to have been selected for the START-UP ... transformative initiative to stimulate economic development in New York ...
(Date:8/21/2014)... 21, 2014  Four-dimensional (4-D) printing develops materials ... external stimuli such as changes in temperature. This ... effect in multiple industries.  In the near future, ... printing objects ranging from human organs to parts ... Logo - http://photos.prnewswire.com/prnh/20140820/138289 ...
(Date:8/21/2014)... August 21, 2014 On Wednesday of last ... to use Redox Signaling molecules, became available for purchase in ... , "The way that RENU 28 works is, if you ... down of the rate of cellular renewal within your body. ... increasing of that rate of cellular renewal. What RENU 28 ...
(Date:8/20/2014)... , Aug. 20, 2014 Neurotrope, ... host a conference call to provide an update ... p.m. Eastern daylight timeDial-in numbers:(888) 505-4369 (U.S. and ... Live web cast: www.neurotropebioscience.com , under "Investor Relations"The ... after completion through September 2, 2014 at (888) ...
Breaking Biology Technology:The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4RENU 28 Skin Care Now Available in Australia and New Zealand 2Neurotrope To Host Conference Call 2
... ANGELES, March 5 Vista Partners announced today,that ... $3.52 price target on Inovio,Biomedical Corporation (Amex: ... regarding the ability of their technology to significantly,enhance ... human results,from three independent clinical studies. The company,s ...
... March 5 , - A New Step Forward ... Administration in Acute Coronary Syndrome Patients, Sanofi-aventis (EURONEXT: ... BMY ) announced today that the Committee for Medicinal,Products ... Agency,(EMEA) has issued a positive opinion recommending approval of ...
... SilOnIS shared the 2007 Jean-Pierre Noblanc ... sustainable project in the EUREKA MEDEA+,microelectronics Cluster. ... and mobile multimedia applications that makes life ... value for network operators. SilOnIS combines strained ...
Cached Biology Technology:Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO) With $3.52 Price Target 2New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP) 2New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP) 3New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP) 4MEDEA+ Noblanc award highlights improvements in microelectronics 2MEDEA+ Noblanc award highlights improvements in microelectronics 3
(Date:8/21/2014)... in smog-producing toxins in past decade, GTA still ... shows that while the Greater Toronto Area (GTA) ... contribute to smog, the city continues to violate ... which can cause or aggravate health problems such ... by a set of complex photochemical reactions involving ...
(Date:8/21/2014)... dandruff, eczema and other itchy, flaky maladies in humans ... Hawaiian coral reefs and the extreme environments of arctic ... the scientific journal PLOS Pathogens considers the ... genus Malassezia in light of new insights ... world. , University of Hawai,i at Mānoa scientist Anthony ...
(Date:8/21/2014)... a key region in the global oceanic circulation. "On the ... Atlantic water flows to the north into the Arctic Ocean ... sea ice push their way out of the Arctic into ... cools here on its way to the north and sinks ... this manner drives the global band of oceanic currents like ...
Breaking Biology News(10 mins):Despite a significant reduction in smog-producing toxins, the Greater Toronto Area still violates Canada's standards for ozone air pollution 2From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2Arctic sea ice influenced force of the Gulf Stream 2Arctic sea ice influenced force of the Gulf Stream 3
... is an intimate and complex relationship between inflammation and cancer; ... chemicals that attract host cells which drive inflammation and help ... by Cell Press in the June issue of the journal ... required for trafficking of immune cells involved in inflammation. ...
... (Minority Access to Research Careers) Program has announced the ... (AAI) Advanced Course in Immunology at The University of ... 2011. These awards are meant to promote the ... the mainstream of the basic science community and to ...
... has been solved with the discovery that the tiny 3 ... use the same buoyancy control as whales. Reporting this ... from British Antarctic Survey describe how Southern Ocean copepods ... deep ocean during winter when seas are stormy and food ...
Cached Biology News:Blocking common gateway to inflammation suppresses cancer 2